150 related articles for article (PubMed ID: 33298868)
1. BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.
Arulananda S; O'Brien M; Evangelista M; Harris TJ; Steinohrt NS; Jenkins LJ; Walkiewicz M; O'Donoghue RJJ; Poh AR; Thapa B; Williams DS; Leong T; Mariadason JM; Li X; Cebon J; Lee EF; John T; Fairlie WD
Cell Death Discov; 2020 Oct; 6(1):114. PubMed ID: 33298868
[TBL] [Abstract][Full Text] [Related]
2. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.
Arulananda S; O'Brien M; Evangelista M; Jenkins LJ; Poh AR; Walkiewicz M; Leong T; Mariadason JM; Cebon J; Balachander SB; Cidado JR; Lee EF; John T; Fairlie WD
Cell Death Discov; 2021 May; 7(1):122. PubMed ID: 34050131
[TBL] [Abstract][Full Text] [Related]
3. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
[TBL] [Abstract][Full Text] [Related]
5. The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.
Arulananda S; Lee EF; Fairlie WD; John T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):413-424. PubMed ID: 33238762
[No Abstract] [Full Text] [Related]
6. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
7. Malignant pleural mesothelioma co-opts BCL-X
Xu D; Liang SQ; Yang Z; Yang H; Bruggmann R; Oberhaensli S; Berezowska S; Marti TM; Hall SRR; Dorn P; Kocher GJ; Schmid RA; Peng RW
Cell Death Dis; 2021 Apr; 12(4):406. PubMed ID: 33859162
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
Varin E; Denoyelle C; Brotin E; Meryet-Figuière M; Giffard F; Abeilard E; Goux D; Gauduchon P; Icard P; Poulain L
Carcinogenesis; 2010 Jun; 31(6):984-93. PubMed ID: 20142415
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
[TBL] [Abstract][Full Text] [Related]
10. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
11. Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors.
Senichkin VV; Pervushin NV; Zamaraev AV; Sazonova EV; Zuev AP; Streletskaia AY; Prikazchikova TA; Zatsepin TS; Kovaleva OV; Tchevkina EM; Zhivotovsky B; Kopeina GS
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008345
[TBL] [Abstract][Full Text] [Related]
12. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
13. Co-operation of MCL-1 and BCL-X
Galas-Filipowicz D; Chavda SJ; Gong JN; Huang DCS; Khwaja A; Yong K
Front Oncol; 2024; 14():1394393. PubMed ID: 38651147
[TBL] [Abstract][Full Text] [Related]
14. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.
Vikström IB; Slomp A; Carrington EM; Moesbergen LM; Chang C; Kelly GL; Glaser SP; Jansen JH; Leusen JH; Strasser A; Huang DC; Lew AM; Peperzak V; Tarlinton DM
Cell Death Dis; 2016 Aug; 7(8):e2345. PubMed ID: 27560714
[TBL] [Abstract][Full Text] [Related]
15. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting BCL-X
Khan S; Kellish P; Connis N; Thummuri D; Wiegand J; Zhang P; Zhang X; Budamagunta V; Hua N; Yang Y; De U; Jin L; Zhang W; Zheng G; Hromas R; Hann C; Zajac-Kaye M; Kaye FJ; Zhou D
Cell Death Discov; 2023 Jan; 9(1):1. PubMed ID: 36588105
[TBL] [Abstract][Full Text] [Related]
17. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells.
Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T
Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models.
Cucarull B; Tutusaus A; Subías M; Stefanovic M; Hernáez-Alsina T; Boix L; Reig M; García de Frutos P; Marí M; Colell A; Bruix J; Morales A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32024199
[TBL] [Abstract][Full Text] [Related]
19. Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-X
Reddy CN; Manzar N; Ateeq B; Sankararamakrishnan R
Biochemistry; 2020 Nov; 59(45):4379-4394. PubMed ID: 33146015
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells.
Abdul Rahman SF; Azlan A; Lo KW; Azzam G; Mohana-Kumaran N
Discov Oncol; 2022 Feb; 13(1):9. PubMed ID: 35201512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
